Another encouraging result in the growth area of antibody-drug conjugates (ADC) reveals a significant survival benefit for people with multiple myeloma.
British pharma major GSK (LSE: GSK) is presenting the data from the Phase III DREAMM-7 trial at the American Society of Clinical Oncology (ASCO) Plenary Series.
Interim data show that a combination treatment featuring Blenrep (belantamab mafodotin) afforded a 59% reduction in the risk of disease progression or death, compared with a Darzalex (daratumumab) combo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze